CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 168 enrolled
Drug / intervention
filgrastim +12 morebiological
Likely dose
Not stated in record
Key inclusion· 8
  • Diagnosis of B-precursor lineage ALL
  • First complete remission duration ≥18 months from initial diagnosis
  • First isolated CNS relapse (WBC ≥5/mm³ in CSF with blasts, or any WBC with immunophenotypic proof of leukemic relapse)
  • First isolated testicular relapse with biopsy confirmation
Key exclusion· 7
  • Down syndrome
  • T-cell ALL or T-cell non-Hodgkin lymphoma
  • Known optic nerve and/or retinal involvement
  • Prior bone marrow transplantation

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00096135
NCT00096135N/ACompleted

Treatment of Late Isolated Extramedullary Relapse From Acute Lymphoblastic Leukemia (ALL) (Initial CR1≥ 18 Months)

Children's Oncology Group·interventional·Posted Nov 9, 2004·Updated Mar 21, 2017

In Brief

A clinical study evaluating filgrastim, cyclophosphamide, and 11 other interventions for Leukemia. Completed, enrolled 168 participants across 153 sites in 5 countries.

Detailed Summary

RATIONALE: Drugs used in chemotherapy work in different ways to stop cancer cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage cancer cells. Giving combination chemotherapy together with radiation therapy may kill more cancer cells. PURPOSE: This clinical trial is studying how well giving chemotherapy together with radiation therapy works in treating patients with acute lymphoblastic leukemia that has relapsed in the CNS and/or testes.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLeukemia
CountriesAustralia, Canada, New Zealand, Switzerland, United States

Timeline

N/ACompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedNov 9, 2004
Enrollment StartNov 1, 2004
Primary CompletionSep 1, 2013
TodayJul 2, 2026
Enrollment to primary: 8.8 yearsPosted 21.6 years ago

Interventions

filgrastimbiological

given subcutaneously (SC)

cyclophosphamidedrug

IV over 15-30 minutes

cytarabinedrug

IV over 3 hours twice daily

daunorubicin hydrochloridedrug

IV over 15 minutes

dexamethasonedrug

oral twice daily

etoposidedrug

IV over 1 hour

leucovorin calciumdrug

rescue IV over 24 hours

mercaptopurinedrug

oral

methotrexatedrug

intramuscularly (IM)

pegaspargasedrug

intramuscularly (IM)

therapeutic hydrocortisonedrug

vincristine sulfatedrug

given IV

radiation therapyradiation

Patients with isolated testicular relapse will start Induction with a single dose of high-dose methotrexate (HDMTX) and will not receive either testicular or cranial radiation. Patients with isolated CNS relapse will NOT receive the initial dose of HDMTX prior to Induction, but will receive 1200 cGy of cranial radiation after completing the initial 12 months of intensive systemic chemotherapy.